Patrick J. Heron - 10 Mar 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role: Director
Signature: /s/ Steve R. Bailey, Attorney-in-Fact For Patrick J. Heron
Issuer symbol: MIRM
Transactions as of: 10 Mar 2025
Net transactions value: +$99,518
Form type: 4
Filing time: 12 Mar 2025, 16:51:20 UTC
Previous filing: 10 Mar 2025
Next filing: 18 Mar 2025
SEC: View on sec.gov

Quoteable Key Fact

"Patrick J. Heron filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 12 Mar 2025."

Quick Takeaways

This page summarizes Patrick J. Heron's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
3 reported transactions and 0 derivative rows are listed below.
Filing timestamp: 12 Mar 2025, 16:51.

What Changed

Previous filing in this sequence was filed on 10 Mar 2025.
Current net transaction value: +$99,518.

Why This Matters

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Transactions Table

MIRM transaction

Common Stock

Purchase

Transaction value: $32,339
Shares: +758
Change %: +0.46%
Price: $42.66
Shares after: 166,583
Date: 10 Mar 2025
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F1, F2

MIRM transaction

Common Stock

Purchase

Transaction value: $25,023
Shares: +577
Change %: +0.35%
Price: $43.37
Shares after: 167,160
Date: 10 Mar 2025
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F2, F3

MIRM transaction

Common Stock

Purchase

Transaction value: $42,155
Shares: +963
Change %: +0.58%
Price: $43.77
Shares after: 168,123
Date: 11 Mar 2025
Ownership: By Frazier Life Sciences X, L.P.
Footnotes: F2, F4

MIRM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,566,912
Date: 10 Mar 2025
Ownership: By Frazier Life Sciences IX, L.P.
Footnotes: F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.42 to $43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4.
F2	The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.20 to $43.50, inclusive.
F4	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $43.405 to $44, inclusive.
F5	The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person is one of two managing members of FHMLS IX, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.